RecruitingNot ApplicableNCT05976490

NeuroPathways Intervention for Brain Tumor Patients

NeuroPathways: An Information and Support Intervention for Patients With Malignant Brain Tumors


Sponsor

Massachusetts General Hospital

Enrollment

50 participants

Start Date

Nov 7, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This goal of this study is to test an information and support intervention for patients with malignant (or "high-grade") brain tumors. This study was developed to help patients cope after a brain tumor diagnosis. The main question this study aims to answer is whether this intervention (which includes access to an information guide and one-on-one coaching sessions) is feasible (i.e., possible to carry out) and acceptable (i.e., considered helpful) to patients. Participants will be asked to take part in the coaching sessions, use the guide as desired, and complete a small group of short surveys at three different points in time; some participants will be asked to share feedback via exit interviews.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Age ≥18
  • Massachusetts General Hospital Cancer Center patient
  • Within 6 weeks of diagnosis with a primary malignant brain tumor
  • Able to speak and read in English

Exclusion Criteria2

  • Inability to provide informed consent as assessed by the study team (e.g., due to neurological impairment such as severe cognitive impairment/dementia or moderate-to-severe receptive aphasia)
  • Deemed inappropriate to approach by patient's oncologist or study PI

Interventions

BEHAVIORALInformation and Support Intervention

Information guide and four one-on-one coaching sessions

OTHERUsual supportive care

Referral to cancer center supportive care services (e.g., social work) upon request from the patient, caregiver, or clinician


Locations(1)

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05976490


Related Trials